FARBRIDGE PHARMA CONSULTING

Serial Number 87736027
Registration 5801310
700

Registration Progress

Application Filed
Dec 27, 2017
Under Examination
Jan 29, 2019
Approved for Publication
Dec 4, 2018
Published for Opposition
Dec 4, 2018
Registered
Jul 9, 2019

Attorney Assistance

Section 8 Declaration Due (Principal Register) (Based on registration date 20190709) (Grace Period Filing)
Due: Jan 09, 2026 Grace Period - 10 days
Original deadline was Jul 09, 2025 (overdue)

Trademark Image

FARBRIDGE PHARMA CONSULTING

Basic Information

Serial Number
87736027
Registration Number
5801310
Filing Date
December 27, 2017
Registration Date
July 9, 2019
Published for Opposition
December 4, 2018
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 9, 2019
Registration
Registered
Classes
045

Rights Holder

Farbridge Pharma Consulting, LLC

16
Address
8525 Gibbs Drive, Suite 304
San Diego, CA 92123

Ownership History

Farbridge Pharma Consulting, LLC

Original Applicant
16
San Diego, CA

Farbridge Pharma Consulting, LLC

Owner at Publication
16
San Diego, CA

Farbridge Pharma Consulting, LLC

Original Registrant
16
San Diego, CA

Legal Representation

Attorney
Edward N. Benito

USPTO Deadlines

Next Deadline
In Grace Period
Section 8 Declaration Due (Principal Register) (Based on registration date 20190709)
Due Date
July 09, 2025
Grace Period Ends
January 09, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

25 events
Date Code Type Description Documents
Jul 9, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jul 9, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 4, 2019 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jun 3, 2019 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
May 31, 2019 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 16, 2019 IUAF S USE AMENDMENT FILED Loading...
May 31, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 16, 2019 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jan 29, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 4, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 4, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 14, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 27, 2018 ALIE A ASSIGNED TO LIE Loading...
Oct 15, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 12, 2018 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Oct 13, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 12, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 12, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 12, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 12, 2018 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 12, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 6, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 13, 2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jan 12, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 30, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 045
Regulatory compliance consulting in the field of drug and device development and manufacturing
First Use Anywhere: May 8, 2019
First Use in Commerce: May 8, 2019

Additional Information

Design Mark
The mark consists of a drawing of an eight-spoke, white wheel on a baby-blue background with four blue arrows circling the wheel in a clockwise direction, with the wheel enclosed by a gray gear or cogwheel, and the gray words "FARBRIDGE PHARMA CONSULTING" to the right of the wheel.
Color Claim
The color(s) gray, white, and blue is/are claimed as a feature of the mark.

Classification

International Classes
045

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA CONSULTING"